Onco Wiki / Regimen

Pembrolizumab + carbo + paclitaxel (endometrial advanced 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

ComponentsDRUG-PEMBROLIZUMAB DRUG-CARBOPLATIN DRUG-PACLITAXEL
IDREG-PEMBRO-CARBO-PACLI-ENDOM
TypeRegimen
Statuspending_clinical_signoff
DiseasesNone declared
SourcesSRC-NCCN-UTERINE-2025

Notes

NRG-GY018: PFS HR 0.64 pMMR, 0.30 dMMR.

Used By

Indication